Alzheimer’s disease doesn’t arrive suddenly. Instead, it emerges slowly, beginning with subtle changes that might be dismissed as normal aging before progressing through increasingly serious stages of ...
On 12 November 2025, Bristol-Myers Squibb conducted a Phase 3 study to Evaluate the Efficacy and Safety of KarXT + KarX-EC ...
An older oral version of the company's semaglutide drug failed to meet its main goal in late-stage trials testing whether the ...
Novo Nordisk's oral semaglutide drug failed in late-stage Alzheimer's trials, leading to a 10% drop in share price. The ...
MedPage Today on MSN
Year in Review: Alzheimer's Disease
News about Alzheimer's rose to the forefront in 2025, as the FDA approved the first diagnostic blood test and drugmakers ...
The results from the two trials of early-stage Alzheimer's patients, called EVOKE and EVOKE+, are another setback for the ...
Novo Nordisk's older oral semaglutide drug failed in late-stage trials aimed at slowing Alzheimer's cognitive decline, ...
Eli Lilly (LLY) rally comes under scrutiny as Novo Nordisk (NVO) readies key late-stage trial results for its GLP-1 pill ...
Novo Nordisk (NVO) announced the top-line results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic ...
A Korean research team has identified the most effective OLED color capable of enhancing cognitive function in Alzheimer's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback